• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢低级别浆液性癌含有非常少的点突变。

Low-grade serous carcinomas of the ovary contain very few point mutations.

机构信息

Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.

出版信息

J Pathol. 2012 Feb;226(3):413-20. doi: 10.1002/path.3967. Epub 2011 Dec 20.

DOI:10.1002/path.3967
PMID:22102435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3503448/
Abstract

It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.

摘要

已经明确的是,卵巢低级别浆液性癌和高级别浆液性癌是两种完全不同的肿瘤类型。虽然高级别浆液性癌的分子遗传学特征现在已经众所周知,但除了认识到涉及 KRAS 和 BRAF 的频繁体细胞突变外,低级别浆液性癌的发病机制在很大程度上仍是未知的。为了全面分析低级别浆液性癌中的体细胞突变,我们对 8 个亲和纯化的低级别浆液性癌样本的 DNA 进行了外显子组测序。在其中的 7 个肿瘤中,只鉴定到数量非常少的突变:在 64 个基因中总共存在 70 个体细胞突变。第 8 个病例显示出混合性浆液性和子宫内膜样特征以及突变子表型,存在 783 个体细胞突变,包括错配修复基因 MSH2 的无义突变。我们在另外 9 个低级别浆液性癌和 10 个浆液性交界性肿瘤(卵巢低级别浆液性癌的前体)中验证了代表性突变。总的来说,最常发生突变的基因是 BRAF 和 KRAS,分别在 27 个低级别肿瘤中的 10 个(38%)和 5 个(19%)中发生。除了一个病例存在 PIK3CA 突变外,在发现集标本中鉴定到的其他突变在验证集标本中均未检测到。我们的突变分析表明,点突变在卵巢低级别浆液性肿瘤中比在其他成人肿瘤中要少见得多,这一发现具有有趣的科学和临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2824/3503448/4bc72edcfc37/nihms411866f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2824/3503448/4bc72edcfc37/nihms411866f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2824/3503448/4bc72edcfc37/nihms411866f1.jpg

相似文献

1
Low-grade serous carcinomas of the ovary contain very few point mutations.卵巢低级别浆液性癌含有非常少的点突变。
J Pathol. 2012 Feb;226(3):413-20. doi: 10.1002/path.3967. Epub 2011 Dec 20.
2
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.卵巢浆液性交界性肿瘤中 KRAS(而非 BRAF)突变与复发性低级别浆液性癌相关。
J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.
3
Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.定义低级别和高级别卵巢浆液性癌之间的切点:一项临床病理和分子遗传学分析。
Am J Surg Pathol. 2009 Aug;33(8):1220-4. doi: 10.1097/PAS.0b013e3181a24354.
4
Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.卵巢浆液性交界性(非典型性增生性)肿瘤及其相关腹膜种植体中 BRAF 和 KRAS 的突变分析。
J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.
5
Molecular characterization of 103 ovarian serous and mucinous tumors.103 例卵巢浆液性和黏液性肿瘤的分子特征分析。
Pathol Oncol Res. 2011 Sep;17(3):551-9. doi: 10.1007/s12253-010-9345-8. Epub 2010 Dec 7.
6
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.在卵巢肿瘤中,BRAF突变(而非KRAS突变)仅限于低级别浆液性肿瘤。
J Pathol. 2004 Mar;202(3):336-40. doi: 10.1002/path.1521.
7
Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.韩国女性卵巢浆液性癌中KRAS、BRAF和TP53基因的突变分析。
Yonsei Med J. 2009 Apr 30;50(2):266-72. doi: 10.3349/ymj.2009.50.2.266.
8
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.非典型增生性(交界性)浆液性肿瘤及低级别微乳头浆液性癌向高级别浆液性癌的发展:形态学及分子遗传学分析
Am J Surg Pathol. 2007 Jul;31(7):1007-12. doi: 10.1097/PAS.0b013e31802cbbe9.
9
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.卵巢低级别和高级别浆液性癌:发病机制、临床病理及分子生物学特征,以及诊断问题
Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa.
10
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.PPP2R1A 突变在卵巢癌各组织学亚型中较为罕见。
Anticancer Res. 2013 Jan;33(1):113-8.

引用本文的文献

1
Targeted Therapies in Low-Grade Serous Ovarian Cancers.低级别浆液性卵巢癌的靶向治疗。
Curr Treat Options Oncol. 2024 Jul;25(7):854-868. doi: 10.1007/s11864-024-01205-4. Epub 2024 Jun 13.
2
Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review.探索卵巢低级别浆液性癌全身治疗的新方法:文献综述
Front Med (Lausanne). 2024 May 21;11:1366603. doi: 10.3389/fmed.2024.1366603. eCollection 2024.
3
Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer-What Can We Learn from Breast Cancer?

本文引用的文献

1
Integrated genomic analyses of ovarian carcinoma.卵巢癌的综合基因组分析。
Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.
2
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.ARID1A 基因突变和表达缺失与子宫低级别子宫内膜样癌。
Am J Surg Pathol. 2011 May;35(5):625-32. doi: 10.1097/PAS.0b013e318212782a.
3
Global cancer statistics.全球癌症统计数据。
雌激素受体阳性卵巢癌的新型内分泌治疗机会——我们能从乳腺癌中学到什么?
Cancers (Basel). 2024 May 13;16(10):1862. doi: 10.3390/cancers16101862.
4
Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.卵巢癌中的致癌途径和靶向治疗。
Biomolecules. 2024 May 15;14(5):585. doi: 10.3390/biom14050585.
5
Advances in precision therapy of low-grade serous ovarian cancer: A review.低级别浆液性卵巢癌精准治疗的进展:综述。
Medicine (Baltimore). 2024 Apr 26;103(17):e34306. doi: 10.1097/MD.0000000000034306.
6
Complete Response With Trametinib in Advanced Low-Grade Serous Ovarian Carcinoma: A Case Report.曲美替尼治疗晚期低级别浆液性卵巢癌获得完全缓解:一例报告
Cureus. 2024 Feb 5;16(2):e53600. doi: 10.7759/cureus.53600. eCollection 2024 Feb.
7
The neurological and non-neurological roles of the primary microcephaly-associated protein ASPM.原发性小头畸形相关蛋白ASPM的神经学和非神经学作用。
Front Neurosci. 2023 Aug 3;17:1242448. doi: 10.3389/fnins.2023.1242448. eCollection 2023.
8
Low-grade serous ovarian cancer: expert consensus report on the state of the science.低级别浆液性卵巢癌:科学现状的专家共识报告。
Int J Gynecol Cancer. 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610.
9
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.原发性卵巢浆液性交界性肿瘤中的KRAS突变与肿瘤复发相关。
Virchows Arch. 2023 Jul;483(1):71-79. doi: 10.1007/s00428-023-03564-z. Epub 2023 May 23.
10
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.低级别浆液性卵巢癌的分子亚型与组织病理学特征及预后相关。
Sci Rep. 2023 May 11;13(1):7681. doi: 10.1038/s41598-023-34627-5.
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
4
The genetic landscape of the childhood cancer medulloblastoma.儿童癌症髓母细胞瘤的遗传特征。
Science. 2011 Jan 28;331(6016):435-9. doi: 10.1126/science.1198056. Epub 2010 Dec 16.
5
ARID1A mutations in endometriosis-associated ovarian carcinomas.ARID1A 突变与子宫内膜异位症相关的卵巢癌。
N Engl J Med. 2010 Oct 14;363(16):1532-43. doi: 10.1056/NEJMoa1008433. Epub 2010 Sep 8.
6
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.卵巢透明细胞癌中染色质重塑基因 ARID1A 的频繁突变。
Science. 2010 Oct 8;330(6001):228-31. doi: 10.1126/science.1196333. Epub 2010 Sep 8.
7
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.BRAF 突变在晚期低级别卵巢浆液性癌中罕见。
Am J Pathol. 2010 Oct;177(4):1611-7. doi: 10.2353/ajpath.2010.100212. Epub 2010 Aug 27.
8
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.RG7204(PLX4032),一种选择性 BRAFV600E 抑制剂,在临床前黑色素瘤模型中显示出强大的抗肿瘤活性。
Cancer Res. 2010 Jul 1;70(13):5518-27. doi: 10.1158/0008-5472.CAN-10-0646. Epub 2010 Jun 15.
9
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.TP53 基因突变在卵巢高级别浆液性癌中普遍存在。
J Pathol. 2010 May;221(1):49-56. doi: 10.1002/path.2696.
10
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.具有微乳头状特征的低恶性潜能肿瘤在分子水平上与卵巢低级别浆液性癌相似。
Gynecol Oncol. 2010 Apr;117(1):9-17. doi: 10.1016/j.ygyno.2010.01.006. Epub 2010 Feb 1.